A J Allen

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Commentary by a child psychiatrist in industry on the assessment of drug safety
    Albert J Allen
    Eli Lilly Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 17:288-91. 2007
  2. ncbi request reprint Drug development process for a product with a primary pediatric indication
    Albert J Allen
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 63:44-9. 2002
  3. ncbi request reprint Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
    A J Allen
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Neurology 65:1941-9. 2005
  4. ncbi request reprint Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Ther 29:1168-77. 2007
  5. ncbi request reprint High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses
    Christopher J Kratochvil
    University of Nebraska Medical Center, Omaha, NE 68198, USA
    J Am Acad Child Adolesc Psychiatry 46:1128-37. 2007
  6. ncbi request reprint Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 17:407-20. 2007
  7. ncbi request reprint A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder
    Susan S F Gau
    Department of Psychiatry, College of Medicine, National Taiwan Universiy, Taipei, Taiwan
    J Child Adolesc Psychopharmacol 17:447-60. 2007
  8. ncbi request reprint Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome
    Thomas J Spencer
    Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Atten Disord 11:470-81. 2008
  9. ncbi request reprint Functional outcomes in the treatment of adults with ADHD
    Lenard A Adler
    Department of Psychiatry, New York University School of Medicine, New York, NY 10010, USA
    J Atten Disord 11:720-7. 2008
  10. ncbi request reprint Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment
    Thomas J Spencer
    Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    J Child Adolesc Psychopharmacol 17:689-700. 2007

Detail Information

Publications31

  1. ncbi request reprint Commentary by a child psychiatrist in industry on the assessment of drug safety
    Albert J Allen
    Eli Lilly Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 17:288-91. 2007
  2. ncbi request reprint Drug development process for a product with a primary pediatric indication
    Albert J Allen
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 63:44-9. 2002
    ....
  3. ncbi request reprint Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
    A J Allen
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Neurology 65:1941-9. 2005
    ..To test the hypothesis that atomoxetine does not significantly worsen tic severity relative to placebo in children and adolescents with attention deficit/hyperactivity disorder (ADHD) and comorbid tic disorders...
  4. ncbi request reprint Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Ther 29:1168-77. 2007
    ..Recently developed nonpsychostimulant treatments have allowed certain patients to switch from a psychostimulant to a nonpsychostimulant. However, the outcomes of such switches have not been systematically studied...
  5. ncbi request reprint High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses
    Christopher J Kratochvil
    University of Nebraska Medical Center, Omaha, NE 68198, USA
    J Am Acad Child Adolesc Psychiatry 46:1128-37. 2007
    ..To assess the utility and tolerability of higher than standard atomoxetine doses to treat attention-deficit/hyperactivity disorder (ADHD)...
  6. ncbi request reprint Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 17:407-20. 2007
    ..ATX was an effective and safe treatment for ADHD in adolescents with ADHD and MDD. However, this trial showed no evidence for ATX of efficacy in treating MDD...
  7. ncbi request reprint A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder
    Susan S F Gau
    Department of Psychiatry, College of Medicine, National Taiwan Universiy, Taipei, Taiwan
    J Child Adolesc Psychopharmacol 17:447-60. 2007
    ..The aim of this study was to assess the efficacy and safety of the once-daily atomoxetine compared with placebo in pediatric patients with attention-deficit/hyperactivity disorder (ADHD) in Taiwan...
  8. ncbi request reprint Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome
    Thomas J Spencer
    Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Atten Disord 11:470-81. 2008
    ..This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS)...
  9. ncbi request reprint Functional outcomes in the treatment of adults with ADHD
    Lenard A Adler
    Department of Psychiatry, New York University School of Medicine, New York, NY 10010, USA
    J Atten Disord 11:720-7. 2008
    ..ADHD is associated with significant functional impairment in adults. The present study examined functional outcomes following 6-month double-blind treatment with either atomoxetine or placebo...
  10. ncbi request reprint Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment
    Thomas J Spencer
    Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    J Child Adolesc Psychopharmacol 17:689-700. 2007
    ..To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine...
  11. ncbi request reprint Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo
    Sitra Tauscher-Wisniewski
    Neuroscience, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Child Adolesc Psychopharmacol 17:713-8. 2007
    ..1% of placebo-treated patients (p = 0.588). This analysis fails to support an association between fluoxetine treatment and increased risk of aggression and/or hostility-related events in children and adolescents compared with placebo...
  12. doi request reprint Meta-analysis of suicide-related behavior events in patients treated with atomoxetine
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 47:209-18. 2008
    ..The present work examined suicide-related events in acute, double-blind, and placebo- or active comparator-controlled trials with atomoxetine...
  13. doi request reprint Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response
    Jeffrey H Newcorn
    Department of Psychiatry, Mount Sinai Medical Center, Box 1230, One Gustave L Levy Place, New York, NY 10029, USA
    Am J Psychiatry 165:721-30. 2008
    ....
  14. doi request reprint Latino versus Caucasian response to atomoxetine in attention-deficit/hyperactivity disorder
    Jorge M Tamayo
    Department of Psychiatry, CES University, Medellin, Colombia
    J Child Adolesc Psychopharmacol 18:44-53. 2008
    ..We found that Latino and Caucasian children with attention-deficit/hyperactivity disorder (ADHD) exhibit a similar pattern of efficacy and tolerability with atomoxetine. The lack of placebo controls was a limitation of this study...
  15. doi request reprint Abuse liability assessment of atomoxetine in a drug-abusing population
    Donald R Jasinski
    Johns Hopkins School of Medicine, Center for Chemical Dependence, 4940 Eastern Avenue, Baltimore, MD 21224, USA
    Drug Alcohol Depend 95:140-6. 2008
    ..This study assessed the abuse potential of atomoxetine in stimulant-preferring drug abusers compared to methylphenidate and phentermine as positive controls and desipramine and placebo as negative controls...
  16. ncbi request reprint Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Am J Psychiatry 159:1896-901. 2002
    ..The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD)...
  17. ncbi request reprint Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine
    Joachim F Wernicke
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
    Dev Med Child Neurol 49:498-502. 2007
    ..The shared vulnerability between ADHD and seizure activity should be taken into account when making treatment decisions for populations of children with epilepsy and children with ADHD...
  18. ncbi request reprint Effects of atomoxetine and methylphenidate on sleep in children with ADHD
    R Bart Sangal
    Clinical Neurophysiology Services, PC, Troy, MI, USA
    Sleep 29:1573-85. 2006
    ..This study also compared the efficacy of these medications for treating ADHD in these children...
  19. ncbi request reprint Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
    David Michelson
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 53:112-20. 2003
    ..To assess the efficacy of atomoxetine, a new and highly selective inhibitor of the norepinephrine transporter, we conducted two large, multicenter treatment trials...
  20. ncbi request reprint Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis IN 46285, USA
    J Clin Psychopharmacol 24:30-5. 2004
    ..It appears that atomoxetine may be discontinued without risk for symptom rebound or discontinuation-emergent adverse effects. Tapering of doses is not necessary when atomoxetine is discontinued...
  21. ncbi request reprint Prevalence of obsessive-compulsive disorder in patients with systemic lupus erythematosus
    Marcia J Slattery
    National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    J Clin Psychiatry 65:301-6. 2004
    ..The goal of this pilot study was to investigate the prevalence of obsessive-compulsive disorder (OCD) in a group of patients with systemic lupus erythematosus (SLE)...
  22. ncbi request reprint Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial
    Douglas K Kelsey
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Pediatrics 114:e1-8. 2004
    ..Another goal was to determine how early in treatment it was possible to discern a specific effect of the drug on ADHD symptoms...
  23. ncbi request reprint Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Saf 31:345-54. 2008
    ..This study describes and assesses potential hepatobiliary events related to atomoxetine therapy, as reported in clinical trials and as spontaneous adverse event reports post-launch in 2002...
  24. ncbi request reprint A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD
    Margaret Weiss
    University of British Columbia, Vancouver, Canada
    J Am Acad Child Adolesc Psychiatry 44:647-55. 2005
    ..The primary objective of this clinical trial was to assess the efficacy of once-daily atomoxetine compared with placebo using teacher reports...
  25. ncbi request reprint Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD
    Lenard Adler
    School of Medicine, New York University, New York, NY, USA
    Ann Clin Psychiatry 18:107-13. 2006
    ..Atomoxetine hydrochloride is an FDA-approved treatment for adult ADHD, but no studies have clarified whether there are advantages to once versus twice daily dosing...
  26. ncbi request reprint Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD
    John Polzer
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 61:713-9. 2007
    ..We systematically examined potential aggression/hostility-related events in a meta-analysis of acute clinical trials of atomoxetine for attention-deficit/hyperactivity disorder (ADHD)...
  27. ncbi request reprint Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder
    Jeffrey H Newcorn
    Mount Sinai Medical Center, Department of Psychiatry, One Gustave L Levy Place, Box 1230, New York, NY 10029, USA
    Pediatrics 118:e1701-6. 2006
    ..However, lower doses could be effective during maintenance treatment, which would reduce drug exposure and potential problems related to tolerability during chronic treatment...
  28. ncbi request reprint Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine
    Lenard A Adler
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    J Clin Psychopharmacol 26:648-52. 2006
    ..Despite the existence of research demonstrating the effects of ADHD on certain aspects of life, the clinical trials of treatments for this disorder have focused primarily on efficacy and safety...
  29. ncbi request reprint Atomoxetine in the treatment of patients with ADHD
    Jan A Gerbers
    Am Fam Physician 71:1879-80; author reply 1880, 1882. 2005
  30. ncbi request reprint Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine
    Amy R Perwien
    Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Dev Behav Pediatr 25:264-71. 2004
    ..Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD...
  31. ncbi request reprint Atomoxetine and tics in ADHD
    Peter D Feldman
    J Am Acad Child Adolesc Psychiatry 44:405-6. 2005